DOCSLIB.ORG

ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors ENETS Consensus Guidelines Neuroendocrinology 2016;103:153–171 Published online: January 5, 2016 DOI: 10.1159/000443171 ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors a b c d e f M. Falconi B. Eriksson G. Kaltsas D.K. Bartsch J. Capdevila M. Caplin g h i j k l B. Kos-Kudla D. Kwekkeboom G. Rindi G. Klöppel N. Reed R. Kianmanesh m R.T. Jensen all other Vienna Consensus Conference participants a b Department of Surgery, San Raffaele Hospital, Università Vita e Salute, Milan , Italy; Department of Endocrine Oncology, c University Hospital, Uppsala , Sweden; Department of Pathophysiology, Division of Endocrinology, National University d e of Athens, Athens , Greece; Department of Surgery, Philipps University, Marburg , Germany; Institute of Oncology f (VHIO), Vall d’Hebron University Hospital, Barcelona , Spain; Neuroendocrine Tumour Unit, Royal Free Hospital, London , g h UK; Department of Endocrinology, Medical University of Silesia, Katowice , Poland; Department of Internal Medicine, i Division of Nuclear Medicine, Erasmus Medical Center, Rotterdam , The Netherlands; Institute of Anatomic Pathology, j Policlinico A. Gemelli, Università Cattolica del Sacro Cuore, Rome , Italy; Institute of Pathology, Technische Universität k l München, Munich , Germany; Beatson Oncology Centre, Gartnavel General Hospital, Glasgow , UK; Department of m Surgery, CHU Robert Debré, Reims , France; Digestive Diseases Branch, NIH, Bethesda, Md. , USA Introduction be considered in three groups: the more frequent gastri- nomas and insulinomas considered independently and Only advances that occurred from 2011 to 2014 that all the rare F-P-NETs (RFTs) considered together and as either strengthen the previous 2011 guidelines [1, 2] or a separate category (Appendix 1 and table 1). lead to changes or additional guidelines are reviewed Most P-NETs occur as sporadic tumors (non-inherit- here. Advances and modifications in the treatment of ad- ed), although a variable proportion of the different F-P- vanced metastatic disease is only briefly dealt with here as NETs occurs as part of an inherited syndrome. MEN1 it is covered in a separate paper in this issue, similar to the remains the most important inherited condition respon- 2011 guideline format [3] . The format used here is the sible for 20–30% of gastrinomas and <5% of insulino- same as that used in the 2011 guidelines with page refer- mas or RFTs [4–7] ; and uncommon causes of inherited ences to the appropriate paper inserted [1, 2] . This docu- P-NETs include von Hippel Lindau disease (VHL), von ment is meant as a supplement to these guidelines and Recklinghausen’s syndrome (neurofibromatosis 1) and does not reiterate all of the points made in the previous tuberous sclerosis [4, 5] . In each of the latter inherited guidelines, only changes, supporting findings or modifi- cations of the 2011 guidelines are thus covered here. M. Falconi, B. Eriksson and G. Kaltsas are co-first authors. As in the previous functional pancreatic neuroendo- For an alphabetical list of all other Vienna Consensus Conference par- crine tumor (F-P-NET) guidelines [1] , the F-P-NETs will ticipants, see Appendix 2. © 2016 S. Karger AG, Basel Prof. Massimo Falconi 0028–3835/16/1032–0153$39.50/0 Ospedale San Raffaele Via Olgettina 60 E-Mail [email protected] IT–20132 Milan (Italy) www.karger.com/nen E-Mail falconi.massimo @ hsr.it Downloaded by: ENETS 198.143.49.33 - 3/14/2016 7:18:44 PM disorders, the patients only rarely develop F-P-NETs, Prognosis and Survival in Sporadic F-P-NETs and with 10–17% of VHL patients developing a non-func- NF-P-NETs tional (NF)-P-NET, <10% of neurofibromatosis 1 pa- tients developing a P-NET, which is almost always a so- Numerous studies have described molecular changes matostatinoma (SSoma) of the duodenum, which is rare- in P-NETs that correlate with prognosis, in most cases not ly functional; and patients with tuberous sclerosis only distinguishing the type of P-NET syndrome. This will be rarely (<1%) develop a F-P-NET or NF-P-NET [4] . Other considered in a later section on the histopathology and rarer syndromes with a possible genetic link are discussed genetics of F-P-NETs. In addition to the prognostic fac- in Appendix 1. tors described in the previous guidelines [1] , recent papers have described further prognostic factors. These include: a the demonstration that the presence of calcifications Epidemiology and Clinicopathological Features on preoperative CT scans in patients with P-NETs (which occurs in 16%) correlates with the grade and The frequency of F-P-NETs, similar to that of NF-P- the presence of lymph node metastasis in well-differ- NETs, and all gastrointestinal NETs [8, 9] continues to be entiated P-NETs [26] ; reported to be increasing in a number of countries [9–13] . b the demonstration that the extent of liver metastasis In some recent series, between 60 and 90% of P-NETs are either unilobar or bilobar or the presence of extra-ab- NF, these are generally diagnosed at more advanced stag- dominal metastasis is an important predictor of sur- es because of their relatively indolent nature and slow vival independent of the tumor grading (Ki-67 index) growth causing a delay in the onset of symptoms. How- [27] ; ever, there is also an exponential increase of incidental c most patients with advanced P-NETs progress over diagnoses of NF-P-NETs which are becoming frequent time, and the best prognosticator for progression was with the widespread use of high-quality imaging tech- the Ki-67 index [28] ; niques [14–16] . d a number of studies now report that in P-NET patients In general, the RFTs and very rare F-P-NETs listed in the presence of positive lymph nodes and their num- table 1 have sufficient numbers of cases or sufficient de- ber have important prognostic value [29–36] . These scriptions of small numbers of cases to verify that they results support the recommendation that a systematic should be considered as established F-P-NET syndromes removal of lymph nodes in the peritumoral area should [17, 18] . A possible exception to this is the case of SSomas. be part of any P-NET operation. However, in the case Recently, the actual existence of a distinct clinical SSoma of lymph node involvement, both the positive nodal syndrome has been questioned because in one extensive status on its own and the number of lymph nodes in- review of cases, none of the 46 patients with pathologi- volved, as well as the ratio between positive lymph cally diagnosed SSomas, nor any of 821 other P-NET cas- nodes and total examined lymph nodes, are important es reviewed, had the full features of the proposed clinical predictors of recurrence after surgery [29, 30] . This SSoma syndrome [19] . will be further discussed in the therapy section below; A small percentage of patients with gastric acid hy- e in one study, the absence of symptoms was associated persecretion and clinical features of Zollinger-Ellison with a significantly better outcome despite the tumour syndrome (ZES) are found to have normal fasting se- stage [28] . Since the incidental diagnoses of P-NETs is rum gastrin (FSG) levels and negative secretin tests [20– becoming more frequent, especially in the case of NF- 22] , and in light of the features of the patient recently P-NETs, with the widespread use of high-quality im- described with a P-NET secreting cholecystokinin aging techniques, this figure can have an impact on (CCKoma) [23] , these patients should have their plasma therapeutic choice [37, 38] . CCK levels assessed. This may be difficult at present be- Numerous recent studies have established the impor- cause only a few groups have proven assays, and recent tance of the different classification and grading systems studies demonstrate that many commercial laboratories for P-NETs and other NETs that have been proposed use poorly characterized antibodies even for such fre- (WHO 2010, ENETS, AJCC/UICC) [9, 39, 40] . In several quent assays as the assessment of serum gastrin levels studies [39, 41–44] , both the classification and grading [24, 25] . have prognostic value, in most cases as an independent variable on multivariate analysis; and therefore it is es- sential not only for the proper treatment strategy, but also 154 Neuroendocrinology 2016;103:153–171 Falconi et al. DOI: 10.1159/000443171 Downloaded by: ENETS 198.143.49.33 - 3/14/2016 7:18:44 PM Table 1. F-P-NET syndromes Name Biologically active Incidence Tumor location Malignant, Associated Main symptoms/signs peptide(s) secreted (new cases/ % with 10 6 popu- MEN-1, % lation/year) The most common F-P-NET syndromes Insulinoma Insulin 1 – 32 Pancreas (>99%) <10 4– 5 Hypoglycemic symptoms (100%) ZES Gastrin 0.5 – 21.5 Duodenum (70%) 60– 90 20– 25 Pain (79– 100%) Pancreas (25%) Diarrhea (30 – 75%) Other sites (5%) Esophageal symptoms (31 – 56%) Established RFT syndromes (>100 cases) VIPoma (Verner-Morrison Vasoactive 0.05 – 0.2 Pancreas (90%, adult) 40– 70 6 Diarrhea (90– 100%) syndrome, pancreatic cholera, intestinal peptide Other (10%, neural, adrenal, Hypokalemic (80 – 100%) WDHA) periganglionic) Dehydration (83%) Glucagonoma Glucagon 0.01 – 0.1 Pancreas (100%) 50– 80 1– 20 Rash (67– 90%) Glucose intolerance (38 – 87%) Weight loss (66 – 96%) SSoma Somatostatin Rare Pancreas (55%) >70 45 Diabetes mellitus (63 – 90%) Duodenum/jejunum (44%) Cholelithiases (65 – 90%) Diarrhea (35 – 90%) GRHoma Growth hormone- Unknown Pancreas (30%) >60 16 Acromegaly (100%) releasing
Load more

Recommended publications
  • Downloaded from Bioscientifica.Com at 09/30/2021 02:21:58AM Via Free Access
    27 8 Endocrine-Related C R C Pieterman, Future directives in 27:8 T9–T25 Cancer S M Sadowski et al. MEN1-related PanNETs THEMATIC REVIEW HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES MEN1-related pancreatic NETs: identification of unmet clinical needs and future directives C R C Pieterman1,2,*, S M Sadowski3,*, J E Maxwell4, M H G Katz4, K E Lines5, C M Heaphy6,†, A Tirosh7, J E Blau8, N D Perrier1, M A Lewis9,10, J P Metzcar11,12, D M Halperin13, R V Thakker5 and G D Valk2 1Section of Surgical Endocrinology, Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA 2Department of Endocrine Oncology, University Medical Center Utrecht, Utrecht, The Netherlands 3Endocrine Surgery, Surgical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA 4Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA 5Academic Endocrine Unit, Radcliffe Department of Medicine, OCDEM, University of Oxford, Oxford, UK 6Departments of Pathology and Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA 7Neuroendocrine Tumors Service, Division of Endocrinology, Metabolism and Diabetes, The Chaim Sheba Medical Center, and Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel 8Metabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA 9Gastrointestinal Oncology, Intermountain
    [Show full text]
  • MEN1-Related Pancreatic Nets: Identification of Unmet Clinical
    27 8 Endocrine-Related C R C Pieterman, Future directives in 27:8 T9–T25 Cancer S M Sadowski et al. MEN1-related PanNETs THEMATIC REVIEW HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES MEN1-related pancreatic NETs: identifcation of unmet clinical needs and future directives C R C Pieterman1,2,*, S M Sadowski3,*, J E Maxwell4, M H G Katz4, K E Lines5, C M Heaphy6,†, A Tirosh7, J E Blau8, N D Perrier1, M A Lewis9,10, J P Metzcar11,12, D M Halperin13, R V Thakker5 and G D Valk2 1Section of Surgical Endocrinology, Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA 2Department of Endocrine Oncology, University Medical Center Utrecht, Utrecht, The Netherlands 3Endocrine Surgery, Surgical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA 4Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA 5Academic Endocrine Unit, Radclife Department of Medicine, OCDEM, University of Oxford, Oxford, UK 6Departments of Pathology and Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA 7Neuroendocrine Tumors Service, Division of Endocrinology, Metabolism and Diabetes, The Chaim Sheba Medical Center, and Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel 8Metabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA 9Gastrointestinal Oncology, Intermountain
    [Show full text]
  • Epigenetic Alterations in Endocrine- Related Cancer
    S Rodrı´guez-Rodero et al. Epigenetics and endocrine 21:4 R319–R330 Review cancer Epigenetic alterations in endocrine- related cancer Sandra Rodrı´guez-Rodero1,2, Elı´as Delgado-A´ lvarez1, Agustı´n F Ferna´ndez2, Juan L Ferna´ndez-Morera1, Edelmiro Mene´ndez-Torre1 and Mario F Fraga2,3 Correspondence 1Endocrinology and Nutrition Service, Hospital Universitario Central de Asturias, Av. Julian Claverı´a s/n, should be addressed 33006 Oviedo, Spain to E Mene´ ndez-Torre or 2Cancer Epigenetics Laboratory, Instituto Universitario de Oncologı´a del Principado de Asturias (IUOPA), M F Fraga Universidad de Oviedo, 33006 Oviedo, Spain Emails 3Department of Immunology and Oncology, National Center for Biotechnology, CNB-CSIC, Cantoblanco, [email protected] or Madrid E-28049, Spain [email protected] Abstract Aberrant epigenetics is a hallmark of cancer, and endocrine-related tumors are no exception. Key Words Recent research has been identifying an ever-growing number of epigenetic alterations in " multiple endocrine both genomic DNA methylation and histone post-translational modification in tumors of the neoplasias endocrine system. Novel microarray and ultra-deep sequencing technologies have allowed " neuroendocrine tumors the identification of genome-wide epigenetic patterns in some tumor types such as " oncology adrenocortical, parathyroid, and breast carcinomas. However, in other cancer types, such " pathogenesis as the multiple endocrine neoplasia syndromes and thyroid cancer, tumor information is limited to candidate genes alone. Future research should fill this gap and deepen our understanding of the functional role of these alterations in cancer, as well as defining Endocrine-Related Cancer their possible clinical uses. Endocrine-Related Cancer (2014) 21, R319–R330 Introduction Epigeneticsisdefinedasthestudyofthosestable However, all such mechanisms in fact cooperate with each genetic modifications that result in changes in function other, and also with other levels of regulation, to establish and gene expression without altering the DNA sequence.
    [Show full text]
  • Endocrine Oncology: Special Issue
    Metab y & o OPEN ACCESS Freely available online g lic lo S o y n n i r d c r o o Endocrinology & Metabolic Syndrome m d n e E ISSN: 2161-1017 Editorial Endocrine Oncology: Special Issue Ilene Fennoy* Department of Pediatrics, Division of Pediatric Diabetes, Endocrinology and Metabolism, Columbia University, New York, New York, USA About Special Issue • Small cell lung cancer Endocrinology & Metabolic Syndrome is an Open Access journal Endocrine pancreatic Tumors with rapid peer-reviewed publishes in the field like biosynthesis, Types of Endocrine pancreatic Tumorsare listed below storage, chemistry, and physiological function of hormones and the cells of endocrine glands and tissues that secrete them. • Non-functioning endocrine pancreatic tumors Endocrinology is happy to announce its Special Issue on “Endocrine • Insulinoma Oncology”. Endocrinology is offering special discounts on APC • Gastrinoma (Article Processing Charges) and immediate publication (within 21days from initial date of submission). Our Journal is planning to • Glucagonoma release issue by end of the Year i.e., Dec 30th, 2020. • VIPoma Endocrine oncologyis a medical specialty deals with the production Adrenals Tumors of hormones and tumors. There are several kinds of endocrine tumors, and are listed below Types of Adrenals Tumorsare listed below • Thyroid Cancer • Adrenocortical carcinoma • Parathyroid Tumors • Pheochromocytoma • Adrenocortical Carcinoma Syndromes of Endocrine Tumor • Pheochromocytoma Types of Syndromes of Endocrine Tumor are listed below • Neuroendocrine Tumors • Multiple Endocrine Neoplasia I, MEN1 • Pituitary Tumors • Multiple Endocrine Neoplasia II, MEN2 Gastrointestinal Tumors • von HippelLindau syndrome Types of gastrointestinal tumours are listed as below We are proud and glad to announce that our journal is ready to release volume 9Issue 7 in this year 2020 and the last issue of this • ECLoma year.
    [Show full text]
  • American Association of Endocrine Surgeons
    THE AMERICAN ASSOCIATION OF ENDOCRINE SURGEONS Thirty-Sixth Annual Meeting MAY 17-19, 2015 The Omni Nashville Hotel Nashville, TN THANK YOU The American Association of Endocrine Surgeons would like to thank the following companies for their generous support of our meeting through educational grants and sponsorships*: Platinum Level Support Neurovision Section of Surgical Sciences, Vanderbilt University Medical Center Gold Level Support Genzyme Silver Level Support Boston Medical Center Ethicon Bronze Level Support AstraZeneca Vanderbilt Endocrine and Eskind Diabetes Clinic Additional support from: Mary Ann Liebert Publishers and Veracyte The American Association of Endocrine Surgeons Foundation would like to thank the following company for their generous support of the Paul LoGerfo Educational Research Award through an annual grant: Elsevier, Inc. The American Association of Endocrine Surgeons gratefully acknowledges the support of the following exhibiting companies*: Akrimax Eisai, Inc. Medtronic Pharmaceuticals EndocrineWeb.com Memorial Healthcare Ambry Genetics Ethicon US, LLC System American Association of Future Diagnostics Neurovision Medical Clinical Endocrinologists GE Healthcare Products, Inc. (AACE) Genzyme, a Sanofi Olympus American Multiple Company Onyx Pharmaceuticals Neoplasia Support Sense Medical (AMEN) Graves’ Disease & Thyroid Foundation Shire American Thyroid Association (ATA) HealthBreeze ThyCa: Thyroid Cancer Survivors’ Association ArborMetrix, Inc. Hitachi Aloka Medical Thyroid Cancer Care CBLPath Interpace Diagnostics
    [Show full text]
  • Diagnosis and Management of Neuroendocrine Tumors Page 1 of 10
    Diagnosis and Management of Neuroendocrine Tumors Page 1 of 10 [ ACP Medicine ] [ MedGenMed eJournal Latest News CME Conferences Resource Centers Patient Ed. Journals & Reference Experts & Viewpoints Search Medscape, MEDLINE and Drug Reference Search Newsletters | Log Out | Return to Medscape coverage of: 8th United European Gastroenterology Week Diagnosis and Management of Neuroendocrine Tumors Disclosures Rudolph Arnold, MD, FRCP Background Definitions and Terminology Endocrine tumors of the digestive system are rare events and present with widely variable and often dramatic clinical syndromes. Several synonyms are currently used by clinicians and pathologists for these tumors, including "carcinoid tumor," "APUD-oma," "gastro-entero-pancreatic (GEP) tumor," "islet cell tumor," "neuroendocrine tumor," and "neuroendocrine carcinoma." The term "carcinoid" was introduced in 1902 by Oberndorfer [1] for malignant tumors arising in the small intestine that formed metastases but differed from other malignancies by a slow tumor growth. [1] The terminology was confined to endocrine tumors of the esophagus, stomach, small and large intestine, and of organs developing from the digestive tract (such as the bronchial system). Pancreatic endocrine tumors, despite revealing histologically many similarities with carcinoids, were excluded from this classification because of the different organogenesis of the pancreas. Recent consensus meetings suggested that the more appropriate term "neuroendocrine tumor" be used for all endocrine tumors of the digestive system, because all such tumors derive from the diffuse neuroendocrine system. [2,3] To this system belong: (a) the pancreas; (b) the mucosa of the gastrointestinal tract containing at least 15 different endocrine cell types producing hormonal peptides and/or biogenic amines [4,5] ; and (c) endocrine cells scattered in other endodermal sites (such as the thyroid, lung, biliary tree, and the urogenital tract).
    [Show full text]
  • Gastroduodenal Neuroendocrine Neoplasms, Including Gastrinoma — Management Guidelines (Recommended by the Polish Network of Neuroendocrine Tumours)
    SZKOLENIE PODYPLOMOWE/POSTGRADUATE EDUCATION Endokrynologia Polska DOI: 10.5603/EP.2017.0016 Tom/Volume 68; Numer/Number 2/2017 ISSN 0423–104X Gastroduodenal neuroendocrine neoplasms, including gastrinoma — management guidelines (recommended by the Polish Network of Neuroendocrine Tumours) Michał Lipiński1*, Grażyna Rydzewska1*, Wanda Foltyn2, Elżbieta Andrysiak-Mamos3**, Agata Bałdys-Waligórska4**, Tomasz Bednarczuk5**, Jolanta Blicharz-Dorniak6**, Marek Bolanowski7**, Agnieszka Boratyn-Nowicka8**, Małgorzata Borowska6**, Andrzej Cichocki9**, Jarosław B. Ćwikła10**, Massimo Falconi11*, Daria Handkiewicz-Junak12**, Alicja Hubalewska-Dydejczyk4**, Barbara Jarząb12**, Roman Junik13**, Dariusz Kajdaniuk14**, Grzegorz Kamiński15**, Agnieszka Kolasińska-Ćwikła16**, Aldona Kowalska17**, Robert Król18**, Leszek Królicki19**, Jolanta Kunikowska19**, Katarzyna Kuśnierz20**, Paweł Lampe20**, Dariusz Lange21**, Anna Lewczuk-Myślicka22**, Andrzej Lewiński23**, Magdalena Londzin-Olesik6**, Bogdan Marek14**, Anna Nasierowska-Guttmejer24**, Ewa Nowakowska-Duława25**, Joanna Pilch-Kowalczyk26**, Karolina Poczkaj6**, Violetta Rosiek2**, Marek Ruchała27**, Lucyna Siemińska14**, Anna Sowa-Staszczak4**, Teresa Starzyńska28**, Katarzyna Steinhof-Radwańska26**, Janusz Strzelczyk2**, Krzysztof Sworczak22**, Anhelli Syrenicz3**, Andrzej Szawłowski29**, Marek Szczepkowski30**, Ewa Wachuła8**, Wojciech Zajęcki6**, Anna Zemczak6**, Wojciech Zgliczyński31**, Beata Kos-Kudła2*** 1Department of Gastroenterology, Central Clinical Hospital of the Ministry of Interior
    [Show full text]
  • Multiple Endocrine Neoplasia Type 1 in Poland: a Two-Centre Experience
    Original paper Endokrynologia Polska DOI: 10.5603/EP.a2019.0031 Volume/Tom 70; Number/Numer 5/2019 ISSN 0423–104X Multiple endocrine neoplasia type 1 in Poland: a two-centre experience Przemysław Soczomski1, Beata Jurecka-Lubieniecka1, Natalia Rogozik2, Andrzej Tukiendorf3, Barbara Jarząb1, Tomasz Bednarczuk2 1Department of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska-Curie Institute — Oncology Centre Gliwice Branch, Gliwice, Poland 2Department of Internal Diseases and Endocrinology, Medical University of Warsaw, Warsaw, Poland 3Department of Public Health, Wroclaw Medical University, Wroclaw, Poland Abstract Introduction: Multiple endocrine neoplasia type 1 (MEN1) has been causing problems for clinicians since it was first described in 1954 by ORIGINAL PAPER Wermer. Not only its rarity, but also its variable clinical manifestations and lack of genotype-phenotype correlation make it hard to establish evidence-based guidelines for the management of this syndrome. Nationwide registers and population-based research are the best means to improve knowledge about this rare disease. As yet, there is no example of such research in the Polish population of MEN1 patients. Material and methods: We performed a retrospective analysis of clinical and genetic data of patients diagnosed with MEN1 syndrome and followed-up in two polish referral centres in the years 1994–2018. Results: We analysed 79 patients, of whom the majority were women. The mean age of the patient population was 43 years, mean age at MEN1 diagnosis was 37.95 years, and mean interval from initial symptoms to MEN1 diagnosis was 6.93 years. Primary hyperparathyroid- ism (PHP), gastroenteropancreatic neuroendocrine tumour (GEP-NET), and pituitary adenoma (PA) developed in 90%, 52%, and 47% of patients, respectively.
    [Show full text]
  • Treatment Options for Pancreatic Neuroendocrine Tumors
    cancers Review Treatment Options for Pancreatic Neuroendocrine Tumors Amit Akirov 1,2,3,* , Vincent Larouche 3,4, Sameerah Alshehri 3, Sylvia L. Asa 5 and Shereen Ezzat 3 1 Institute of Endocrinology, Beilinson Hospital, Petach Tikva 49100, Israel 2 Sackler School of Medicine, Tel Aviv University, Tel Aviv 69978, Israel 3 Department of Endocrine Oncology, Princess Margaret Cancer Centre, Toronto, ON M5G 1Z5, Canada; [email protected] (V.L.); [email protected] (S.A.); [email protected] (S.E.) 4 Department of Medicine, Division of Endocrinology and Metabolism, Jewish General Hospital, McGill University, Montreal, QC H3T 1E2, Canada 5 Department of Pathology, University Health Network, University of Toronto, Toronto, ON M5S 1A1, Canada; [email protected] * Correspondence: [email protected]; Tel.: +972-524650760; Fax: +972-3-9377181 Received: 24 May 2019; Accepted: 12 June 2019; Published: 14 June 2019 Abstract: The management of pancreatic neuroendocrine tumors (PanNETs) involves classification into non-functional or functional PanNET, and as localized or metastatic PanNET. In addition, while most PanNETs are sporadic, these endocrine neoplasms can also be manifestations of genetic syndromes. All these factors may assist in forming a risk stratification system permitting a tailored management approach. Most PanNETs are classified as non-functional because they are not associated with clinical sequelae of hormone excess. They are characterized by non-specific symptoms, such as abdominal pain or weight loss, resulting from mass effect related to the pancreatic tumor or secondary to distant metastases. Accurate staging of the disease is essential for determining the appropriate approach to therapy. As cure is only potentially possible with surgical resection of the tumor, it is recommended to remove all localized and limited metastatic disease.
    [Show full text]
  • Cancers of the Endocrine Organs – Endocrine Neoplasms Preferred Model of Care and Criteria for Reference Centres
    CANCERS OF THE ENDOCRINE ORGANS – ENDOCRINE NEOPLASMS PREFERRED MODEL OF CARE AND CRITERIA FOR REFERENCE CENTRES Coordinators: Giuseppe COSTANTE (Endocrinology, Institut Jules Bordet), Ahmad AWADA (Medical oncology, Institut Jules Bordet). Authors : Giuseppe COSTANTE (Endocrinology, Institut Jules Bordet), Kris POPPE (Endocrinology, VUB), Laurent VROONEN (Endocrinology, CHU Liège), Bruno LAPAUW (Endocrinology, UZ Gent), Isabelle SALMON (Pathology, Erasme), Guy ANDRY (Head and neck surgery, Institut Jules Bordet), Ahmad AWADA (Medical oncology, Institut Jules Bordet). Disclaimer : The coordinators of the working groups and all the authors listed by chapter have worked autonomously under the supervision of the KCE team. The KCE experts are not co-authors of these proposals and did not necessarily validate their content. Hospitals with which coordinators and authors of these proposals are affiliated are not de facto considered Reference Centres. Similarly, Belgian hospitals that are not represented in these proposals are not de facto considered Peripheral Centres. These proposals were not submitted to the external validators. This addendum only exists in English. No French or Dutch translation was done. Finally, the report to which this addendum refers has been approved by common assent by the Executive Board. Copyright : KCE reports are published under a “by/nc/nd” Creative Commons Licence http://kce.fgov.be/content/about-copyrights-for-kce-reports. This section is part of a whole document (KCE Report 219 Addendum) available on the
    [Show full text]
  • Tumours Producing Hypoglycaemia
    Endocrine-Related Cancer (1998) 5 111-129 Tumours producing hypoglycaemia V Marks and J D Teale European Institute of Health and Medical Sciences, University of Surrey, Guildford GU2 5RF, UK and Department of Clinical Biochemistry and Nutrition, Royal Surrey County Hospital, Guildford GU2 5XX, UK (Requests for offprints should be addressed to V Marks) Introduction Classification of hypoglycaemia- Hypoglycaemia is one of the commonest of medical producing tumours emergencies, mainly due to its high frequency as a Tumours producing hypoglycaemia can, broadly complication of insulin therapy of diabetes. It sometimes speaking, be divided - on the basis of the mechanism by arises, however, ‘spontaneously’ as a manifestation of which they most commonly produce hypoglycaemia - other diseases. The present review deals exclusively with into: (1) insulin-secreting tumours; (2) non-islet cell hypoglycaemia caused by neoplastic disease. (insulin-like growth factor-II (IGF-II)-secreting) tumours; For a very brief period, between 1927 and 1930, (3) myeloma, lymphoma and leukaemia; and (4) meta- tumours capable of producing hypoglycaemia were static neoplasia. thought always to secrete insulin and arise exclusively Hypoglycaemia produced by tumours other than within the pancreas. In the intervening years it has become insulinomas is usually referred to as ‘non-islet cell tumour increasingly apparent that almost any type of neoplasm hypoglycaemia’ (NICTH) and has more than one cause. can cause hypoglycaemia through a number of different mechanisms (Marks & Rose 1964, Laurent et al. 1971, Pancreatic endocrine tumours Daughaday 1989, Fajans & Vinik 1989). Insulin-secreting tumours are the commonest hormone- producing neoplasms of the gastrointestinal tract. They Symptomatology occur with an incidence of between 0.5 and 1 per million of the population per year (Kavlie & White 1972, Hypoglycaemia may be the presenting symptom of a Atkinson et al.
    [Show full text]